Migalastat (Galafold®)

Assessment Status Assessment Process Complete
Drug Migalastat
Brand Galafold®
Indication For the long term treatment of adult and adolescent patients 16 years and older with a confirmed diagnosis of Fabry disease and who have an amenable mutation.
Assessment Process
Rapid review commissioned 14/07/2016
Rapid review completed 18/08/2016
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 03/01/2017
NCPE assessment completed 01/06/2017
NCPE assessment outcome Reimbursement Recommended

Technical Summary

The NCPE recommends reimbursement of Migalastat (Galafold®) subject to the continuing availability of a patient access scheme.